The power of the Nanobody platform is such that Ablynx has the opportunity to generate development candidates across a range of therapeutic areas in just over two years. The breadth of the Nanobody platform and the efficiency with which leads are generated has created partnering opportunities ranging from early-stage leads to clinical-stage licensing opportunities.

To learn more about drug discovery collaborations and licensing opportunities with Ablynx, please contact our Business Development department.